Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-003885-19
    Sponsor's Protocol Code Number:NOT-APPLICABLE-HUFA
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-03-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2022-003885-19
    A.3Full title of the trial
    ECOGUIDED GENICULAR NERVE BLOCK IN PATIENTS WITH KNEE OSTEOARTHRITIS BY LOCAL ANESTHETIC OR BY COMBINATION OF LOCAL ANESTHETIC AND CORTICOID: PLACEBO-CONTROLLED RANDOMIZED BLIND CLINICAL TRIAL
    BLOQUEO ECOGUIADO DE NERVIOS GENICULARES DE RODILLA EN PACIENTES CON GONARTROSIS MEDIANTE ANESTÉSICO LOCAL O MEDIANTE LA COMBINACIÓN DE ANESTÉSICO LOCAL CON CORTICOIDE: ENSAYO CLÍNICO PILOTO CIEGO ALEATORIZADO CONTROLADO CON PLACEBO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    TREATMENT OF KNEE PAIN IN PATIENTS WITH OSTEOARTHRITIS THROUGH THE COMBINATION OF LOCAL ANESTHETIC WITH CORTICOID OR ISOLATED LOCAL ANESTHETIC
    TRATAMIENTO DEL DOLOR DE RODILLA EN PACIENTES CON ARTROSIS MEDIANTE LA COMBINACIÓN DE ANESTÉSICO LOCAL CON CORTICOIDE O ANESTÉSICO LOCAL AISLADO
    A.3.2Name or abbreviated title of the trial where available
    ECOGUIDED GENICULAR NERVE BLOCK. PLACEBO-CONTROLLED RANDOMIZED BLIND PILOT CLINICAL TRIAL
    BLOQUEO DE NERVIOS GENICULARES ECOGUIADO. ESTUDIO PILOTO CIEGO ALEATORIZADO CONTROLADO CON PLACEBO
    A.4.1Sponsor's protocol code numberNOT-APPLICABLE-HUFA
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNO-COMERCIAL
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNO COMERCIAL
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNO-COMERCIAL
    B.5.2Functional name of contact pointNA
    B.5.3 Address:
    B.5.3.1Street AddressNA
    B.5.3.2Town/ cityNA
    B.5.3.4CountrySpain
    B.5.6E-mailclaudia.fuente@salud.madrid.org
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Bupivacaine
    D.2.1.1.2Name of the Marketing Authorisation holderBraun
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBupivacaine
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInfiltration
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name sodium chloride
    D.2.1.1.2Name of the Marketing Authorisation holderFRESENIUS KABI
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namesodium chloride
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInfiltration
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name TRIGON DEPOT
    D.2.1.1.2Name of the Marketing Authorisation holderBristol-Myers Squibb
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTRIGON DEPOT
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInfiltration
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInjection
    D.8.4Route of administration of the placeboInfiltration
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    KNEE OSTEOARTHRITIS
    E.1.1.1Medical condition in easily understood language
    KNEE PAIN DUE TO OSTEOARTHRITIS
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the efficacy of genicular nerve block using local anesthetic with and without corticosteroids versus a control group to relieve pain in patients with gonarthrosis who are simultaneously treated with physiotherapy exercises.
    Comparar la eficacia del bloqueo de los nervios geniculares mediante anestésico local con y sin corticoide frente a grupo control para aliviar el dolor en pacientes con gonartrosis que realizan al mismo tiempo tratamiento mediante ejercicios de fisioterapia.
    E.2.2Secondary objectives of the trial
    Evaluate secondary effects and/or interactions to the technique
    Assess the decrease in the consumption of analgesic medication
    Evaluate improvement of the functionality/quality of life of the patient
    Assess the patient's state of mind before and after the technique
    Assess physiotherapy (outpatient vs. hospital) and adherence to exercise
    Valorar efectos secundarios y/o interacciones a la técnica
    Valorar la disminución de consumo de medicación analgésica
    Valorar mejoría de la funcionalidad/calidad de vida del paciente
    Valorar el estado anímico del paciente antes y después de la técnica
    Valorar fisioterapia (ambulatoria vs hospitalaria) y adherencia al ejercicio
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Anterior knee pain of patellofemoral origin and/or tibiofemoral compartment osteoarthritis
    Pain assessment scale (VAS) ≥ 5
    3 months of evolution
    Dolor anterior de rodilla de origen patelofemoral y/o artrosis de compartimento femorotibial
    Escala de valoración de dolor (EVA) ≥ 5
    3 meses de evolución
    E.4Principal exclusion criteria
    Under 18 years
    Patients who underwent total or unicompartmental knee replacement
    Viscosupplementation or intra-articular injection with corticosteroids for less than 3 months
    Pregnant women or women suspected of being pregnant
    Cognitive impairment or added neuropsychiatric symptoms
    Failure to sign informed consent or revocation of it
    In a radiological study using the Kellgren-Lawrence classification with a value <2
    Patients with heart disease who require blockade with levobupivacaine
    Inability to write, speak or read in Spanish
    Active tumor or infectious pathology
    Osteoarthritis secondary to inflammatory pathology
    Menores de 18 años
    Pacientes intervenidos mediante prótesis total o unicompartimental de rodilla
    Viscosuplementación o inyección intraarticular con corticoides menos de 3 meses
    Mujeres embarazadas o con sospecha de que lo pueden estar
    Deterioro cognitivo o síntomas neuropsiquiátricos añadidos
    No firmar consentimiento informado o revocación de éste
    En estudio radiológico mediante la clasificación de Kellgren- Lawrence con valor <2
    Pacientes con cardiopatía que precisen bloqueo mediante levobupivacaína
    Incapacidad para escribir, hablar o leer en español
    Patología tumoral o infecciosa activa
    Artrosis secundaria a patología inflamatoria
    E.5 End points
    E.5.1Primary end point(s)
    Genicular nerve block with local anesthetic in patients with painful gonarthrosis improves pain, functionality-quality of life of the patient and decreases the consumption of analgesics with equal or better results than local anesthetic associated with corticosteroids.
    El bloqueo de los nervios geniculares mediante anestésico local en pacientes con gonartrosis dolorosa mejora el dolor, funcionalidad-calidad de vida del paciente y disminuye el consumo de analgésicos con igual o mejor resultado que el anestésico local asociado a corticoide.
    E.5.1.1Timepoint(s) of evaluation of this end point
    MARCH 2024
    E.5.2Secondary end point(s)
    MARCH 2024
    E.5.2.1Timepoint(s) of evaluation of this end point
    July 2022: Study approach and start with the bibliographic review
    November 2022: Registration as a clinical trial and presentation to the ethics and clinical research committee. (Answer pending)
    January 2023: After obtaining approval from the CEIC, the data will be collected anonymously and coding the participants.
    August 2023: End of data collection.
    March 2024: Analysis of the results obtained, and elaboration of the conclusions.
    Julio 2022: Planteamiento del estudio y comenzar con la revisión bibliográfica
    Noviembre 2022: Registro como ensayo clínico y presentación a comité de ética e investigación clínica. (Pendiente de respuesta)
    Enero 2023: Tras obtener aprobación por parte de CEIC se procederá a la recogida de datos de forma anónima y codificando a los participantes.
    Agosto 2023: Fin de recogida de datos.
    Marzo 2024: Análisis de los resultados obtenidos, y elaboración de las conclusiones.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The objective would be to create a new coordination unit between the Rehabilitation and Orthopedic Surgery and Traumatology unit to create a rehabilitation program for patients who are going to undergo surgery using total or unicompartmental knee replacement.
    El objetivo sería crear una nueva unidad de coordinación entre la unidad de Rehabilitación y Cirugía Ortopédica y Traumatología para crear un programa de rehabilitación en pacientes que vayan a ser sometidos a una intervención quirúrgica mediante prótesis total o unicompartimental de rodilla.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 90
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 90
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state90
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    When THE participation ends, the participants will continue to receive the same follow-up and treatment from external Rehabilitation and Traumatology consultations. In other words, inclusion in this study does not exclude other medical-surgical treatments in the future.
    Cuando acabe la participación, continuarán recibiendo el mismo seguimiento y el tratamiento por parte de consultas externas de Rehabilitación y Traumatología. Es decir, la inclusión a este estudio no excluye de otros tratamientos médico-quirúrgicos en el futuro.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-03-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-03-02
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 01:39:14 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA